胰腺神经内分泌肿瘤的药物治疗进展
Advances in Drug Therapy for Pancreatic Neuroendocrine Tumor
DOI: 10.12677/jcpm.2025.45452, PDF,   
作者: 邱 文：延安大学医学院，陕西 延安；黄 新*：延安大学医学院，陕西 延安；西安市中心医院普外一科，陕西 西安
关键词: 胰腺神经内分泌瘤；药物治疗；进展；Pancreatic Neuroendocrine Tumor； Drug Therapy； Progress
摘要: 胰腺神经内分泌肿瘤(Pancreatic neuroendocrine tumors, PNETs)起病隐匿，生物学行为呈高度异质性，肿瘤可表现为惰性生长，亦可表现为侵袭性生长，甚至早期发生转移，且其生物学特性可能随着疾病的进展而发生变化。近年来，随着各种诊断技术手段的不断发展以及大众健康体检的普及，PNETs的发病率呈现明显的上升趋势，随之各种治疗方法相继出现。然而，PNETs可表现为散发性或遗传相关性，也可因肿瘤的激素分泌功能导致相应的激素相关症状或综合征，且不同分级、分期的PNETs在预后上存在较大差异。因此PNETs诊疗决策的制定需要经过综合全面的考量，制定个性化治疗方案。本文主要对目前PENTs的药物治疗进展作相关性综述。
Abstract: Pancreatic neuroendocrine tumors (PNETs) are characterized by their insidious onset and highly heterogeneous biological behavior. The tumors can exhibit indolent growth, aggressive growth, or even metastasize at an early stage, with their biological characteristics potentially changing as the disease progresses. In recent years, with the continuous development of various diagnostic techniques and the popularization of public health check-ups, the incidence of PNETs has shown a significant upward trend, followed by the emergence of various treatment methods. However, PNETs can present as sporadic or hereditary, and may also cause corresponding hormonal symptoms or syndromes due to the hormonal secretion function of the tumor. There are significant differences in prognosis among PNETs of different grades and stages. Therefore, the formulation of diagnostic and treatment decisions for PNETs requires comprehensive consideration and the development of personalized treatment plans. This article mainly reviews the current progress in drug treatment for PNETs.
文章引用：邱文, 黄新. 胰腺神经内分泌肿瘤的药物治疗进展[J]. 临床个性化医学, 2025, 4(5): 1-8. https://doi.org/10.12677/jcpm.2025.45452

参考文献

[1] Kidd, M., Modlin, I. and Öberg, K. (2016) Towards a New Classification of Gastroenteropancreatic Neuroendocrine Neoplasms. Nature Reviews Clinical Oncology, 13, 691-705. [Google Scholar] [CrossRef] [PubMed]
[2] Scarpa, A., Chang, D.K., Nones, K., et al. (2017) Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours. Nature, 543, 65-71. [Google Scholar] [CrossRef] [PubMed]
[3] Gaztambide, S., Vazquez, F. and Castaño, L. (2013) Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 1 (MEN1). Minerva Endocrinology, 38, 17-28.
[4] Tirosh, A., Sadowski, S.M., Linehan, W.M., Libutti, S.K., Patel, D., Nilubol, N., et al. (2018) Association of VHL Genotype with Pancreatic Neuroendocrine Tumor Phenotype in Patients with Von Hippel-Lindau Disease. JAMA Oncology, 4, 124-126. [Google Scholar] [CrossRef] [PubMed]
[5] Amarjothi, J., Jesudason, J., Ramasamy, V. and Babu, O.N. (2019) Interesting Pancreatic Tumour in the Background of Tuberous Sclerosis. BMJ Case Reports, 12, e227292. [Google Scholar] [CrossRef] [PubMed]
[6] Crona, J., Norlén, O., Antonodimitrakis, P., Welin, S., Stålberg, P. and Eriksson, B. (2016) Multiple and Secondary Hormone Secretion in Patients with Metastatic Pancreatic Neuroendocrine Tumours. The Journal of Clinical Endocrinology & Metabolism, 101, 445-452. [Google Scholar] [CrossRef] [PubMed]
[7] Luo, G., Liu, Z., Guo, M., Jin, K., Xiao, Z., Liu, L., et al. (2015) A Comprehensive Comparison of Clinicopathologic and Imaging Features of Incidental/Symptomatic Non-Functioning Pancreatic Neuroendocrine Tumors: A Retrospective Study of a Single Center. Pancreatology, 15, 519-524. [Google Scholar] [CrossRef] [PubMed]
[8] Nagtegaal, I.D., Odze, R.D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., et al. (2019) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188. [Google Scholar] [CrossRef] [PubMed]
[9] Oronsky, B., Ma, P.C., Morgensztern, D. and Carter, C.A. (2017) Nothing but NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia, 19, 991-1002. [Google Scholar] [CrossRef] [PubMed]
[10] Hauso, O., Gustafsson, B.I., Kidd, M., Waldum, H.L., Drozdov, I., Chan, A.K.C., et al. (2008) Neuroendocrine Tumor Epidemiology. Cancer, 113, 2655-2664. [Google Scholar] [CrossRef] [PubMed]
[11] Ito, T., Igarashi, H., Nakamura, K., Sasano, H., Okusaka, T., Takano, K., et al. (2015) Epidemiological Trends of Pancreatic and Gastrointestinal Neuroendocrine Tumors in Japan: A Nationwide Survey Analysis. Journal of Gastroenterology, 50, 58-64. [Google Scholar] [CrossRef] [PubMed]
[12] Fan, J., Zhang, Y., Shi, S., Chen, Y., Yuan, X., Jiang, L., et al. (2017) A Nation-Wide Retrospective Epidemiological Study of Gastroenteropancreatic Neuroendocrine Neoplasms in China. Oncotarget, 8, 71699-71708. [Google Scholar] [CrossRef] [PubMed]
[13] Wu, W., Jin, G., Li, H., Miao, Y., Wang, C., Liang, T., et al. (2019) The Current Surgical Treatment of Pancreatic Neuroendocrine Neoplasms in China: A National Wide Cross-Sectional Study. Journal of Pancreatology, 2, 35-42. [Google Scholar] [CrossRef] 
[14] Zheng, R., Zhao, H., An, L., Zhang, S., Chen, R., Wang, S., et al. (2023) Incidence and Survival of Neuroendocrine Neoplasms in China with Comparison to the United States. Chinese Medical Journal, 136, 1216-1224. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, J., Liu, J., He, C., Sun, T., Yan, Y., Che, G., et al. (2021) Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016. Journal of Oncology, 2021, Article ID: 4302675. [Google Scholar] [CrossRef] [PubMed]
[16] Stang, A., Wellmann, I., Holleczek, B., Kim-Wanner, S., Müller-Nordhorn, J., Sirri, E., et al. (2024) Incidence and Survival of Patients with Malignant Pancreatic Neuroendocrine Neoplasms in Germany, 2009-2021. Cancer Epidemiology, 93, Article 102659. [Google Scholar] [CrossRef] [PubMed]
[17] Chang, J.S., Chen, L., Shan, Y., Chu, P., Tsai, C. and Tsai, H. (2021). Scientific Reports, 11, Article No. 7881.[CrossRef] [PubMed]
[18] Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T.M., et al. (2016) Placebo-controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology, 104, 26-32. [Google Scholar] [CrossRef] [PubMed]
[19] Caplin, M.E., Pavel, M. and Ruszniewski, P. (2014) Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 371, 1556-1557.
[20] Caplin, M.E., Pavel, M., Ćwikła, J.B., Phan, A.T., Raderer, M., Sedláčková, E., et al. (2014) Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine, 371, 224-233. [Google Scholar] [CrossRef] [PubMed]
[21] Rinke, A., Müller, H., Schade-Brittinger, C., Klose, K., Barth, P., Wied, M., et al. (2009) Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group. Journal of Clinical Oncology, 27, 4656-4663. [Google Scholar] [CrossRef] [PubMed]
[22] 吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020) [J]. 中华外科杂志, 2021, 59(6): 401-421.
[23] Jann, H., Denecke, T., Koch, M., Pape, U.F., Wiedenmann, B. and Pavel, M. (2013) Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin. Neuroendocrinology, 98, 137-143. [Google Scholar] [CrossRef] [PubMed]
[24] Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M.A., et al. (2015) Phase III Study of Pasireotide Long-Acting Release in Patients with Metastatic Neuroendocrine Tumors and Carcinoid Symptoms Refractory to Available Somatostatin Analogues. Drug Design, Development and Therapy, 9, 5075-5086. [Google Scholar] [CrossRef] [PubMed]
[25] Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D.K., Capdevila, J., Caplin, M., et al. (2016) ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 103, 153-171. [Google Scholar] [CrossRef] [PubMed]
[26] Pestka, S. (1983) The Human Interferons—From Protein Purification and Sequence to Cloning and Expression in Bacteria: Before, between, and Beyond. Archives of Biochemistry and Biophysics, 221, 1-37. [Google Scholar] [CrossRef] [PubMed]
[27] Fleischmann, W.R., Koren, S. and Fleischmann, C.M. (1992) Orally Administered Interferons Exert Their White Blood Cell Suppressive Effects via a Novel Mechanism. Experimental Biology and Medicine, 201, 200-207. [Google Scholar] [CrossRef] [PubMed]
[28] Motylewska, E., Lawnicka, H., Kowalewicz-Kulbat, M., Sicinska, P., Niedziela, A., Melen-Mucha, G., et al. (2013) Interferon Alpha and Rapamycin Inhibit the Growth of Pheochromocytoma PC12 Line in Vitro. Endokrynologia Polska, 64, 368-374. [Google Scholar] [CrossRef] [PubMed]
[29] Öberg, K. (2000) Interferon in the Management of Neuroendocrine GEP-Tumors. Digestion, 62, 92-97. [Google Scholar] [CrossRef] [PubMed]
[30] Pavel, M.E., Baum, U., Hahn, E.G., Schuppan, D. and Lohmann, T. (2006) Efficacy and Tolerability of Pegylated IFN-Α in Patients with Neuroendocrine Gastroenteropancreatic Carcinomas. Journal of Interferon & Cytokine Research, 26, 8-13. [Google Scholar] [CrossRef] [PubMed]
[31] Pavel, M., Jann, H., Prasad, V., Drozdov, I., Modlin, I.M. and Kidd, M. (2016) NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology, 104, 170-182. [Google Scholar] [CrossRef] [PubMed]
[32] Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin, E.M., Van Cutsem, E., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364, 514-523. [Google Scholar] [CrossRef] [PubMed]
[33] Raymond, E., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard-Bohas, C., et al. (2011) Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364, 501-513. [Google Scholar] [CrossRef] [PubMed]
[34] Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, X., et al. (2020) Surufatinib in Advanced Pancreatic Neuroendocrine Tumours (SANET-P): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 1489-1499. [Google Scholar] [CrossRef] [PubMed]
[35] Shah, M.H., Goldner, W.S., Benson, A.B., et al. (2021) Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 839-868.
[36] Zhao, J., Zhao, H. and Chi, Y. (2018) Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. Neuroendocrinology, 106, 318-323. [Google Scholar] [CrossRef] [PubMed]
[37] Strosberg, J.R., Fine, R.L., Choi, J., Nasir, A., Coppola, D., Chen, D., et al. (2011) First‐Line Chemotherapy with Capecitabine and Temozolomide in Patients with Metastatic Pancreatic Endocrine Carcinomas. Cancer, 117, 268-275. [Google Scholar] [CrossRef] [PubMed]
[38] Pavel, M., Öberg, K., Falconi, M., Krenning, E.P., Sundin, A., Perren, A., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 844-860. [Google Scholar] [CrossRef] [PubMed]
[39] Rogowski, W., Wachuła, E., Gorzelak, A., Lebiedzińska, A., Sulżyc-Bielicka, V., Iżycka-Świeszewska, E., et al. (2019) Capecitabine and Temozolomide Combination for Treatment of High-Grade, Well-Differentiated Neuroendocrine Tumour and Poorly-Differentiated Neuroendocrine Carcinoma—Retrospective Analysis. Endokrynologia Polska, 70, 313-317. [Google Scholar] [CrossRef] [PubMed]
[40] Mitry, E., Baudin, E., Ducreux, M., Sabourin, J., Rufié, P., Aparicio, T., et al. (1999) Treatment of Poorly Differentiated Neuroendocrine Tumours with Etoposide and Cisplatin. British Journal of Cancer, 81, 1351-1355. [Google Scholar] [CrossRef] [PubMed]
[41] Iwasa, S., Morizane, C., Okusaka, T., Ueno, H., Ikeda, M., Kondo, S., et al. (2010) Cisplatin and Etoposide as First-Line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. Japanese Journal of Clinical Oncology, 40, 313-318. [Google Scholar] [CrossRef] [PubMed]
[42] Sorbye, H., Welin, S., Langer, S.W., Vestermark, L.W., Holt, N., Osterlund, P., et al. (2013) Predictive and Prognostic Factors for Treatment and Survival in 305 Patients with Advanced Gastrointestinal Neuroendocrine Carcinoma (WHO G3): The NORDIC NEC Study. Annals of Oncology, 24, 152-160. [Google Scholar] [CrossRef] [PubMed]
[43] Douangprachanh, S., Joo, H.J., Park, H.M., Han, N., Jang, H.Y., Koh, Y.H., et al. (2022) Capecitabine and Temozolomide for Metastatic Intermediate to High-Grade Pancreatic Neuroendocrine Neoplasm: A Single Center Experience. The Korean Journal of Internal Medicine, 37, 1216-1222. [Google Scholar] [CrossRef] [PubMed]
[44] de Mestier, L., Walter, T., Evrard, C., de Boissieu, P., Hentic, O., Cros, J., et al. (2020) Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. Neuroendocrinology, 110, 83-91. [Google Scholar] [CrossRef] [PubMed]
[45] Kunz, P.L., Graham, N.T., Catalano, P.J., Nimeiri, H.S., Fisher, G.A., Longacre, T.A., et al. (2023) Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology, 41, 1359-1369. [Google Scholar] [CrossRef] [PubMed]
[46] Binnewies, M., Roberts, E.W., Kersten, K., Chan, V., Fearon, D.F., Merad, M., et al. (2018) Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. [Google Scholar] [CrossRef] [PubMed]
[47] Cives, M., Pelle’, E., Quaresmini, D., Rizzo, F.M., Tucci, M. and Silvestris, F. (2019) The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 109, 83-99. [Google Scholar] [CrossRef] [PubMed]
[48] Katz, S.C., Donkor, C., Glasgow, K., Pillarisetty, V.G., Gönen, M., Espat, N.J., et al. (2010) T Cell Infiltrate and Outcome Following Resection of Intermediate-Grade Primary Neuroendocrine Tumours and Liver Metastases. HPB, 12, 674-683. [Google Scholar] [CrossRef] [PubMed]
[49] Lamarca, A., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., McNamara, M.G., et al. (2018) PD-L1 Expression and Presence of Tils in Small Intestinal Neuroendocrine Tumours. Oncotarget, 9, 14922-14938. [Google Scholar] [CrossRef] [PubMed]
[50] Strosberg, J., Mizuno, N., Doi, T., Grande, E., Delord, J., Shapira-Frommer, R., et al. (2020) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study. Clinical Cancer Research, 26, 2124-2130. [Google Scholar] [CrossRef] [PubMed]
[51] Roberts, J.A., Gonzalez, R.S., Das, S., Berlin, J. and Shi, C. (2017) Expression of PD-1 and PD-L1 in Poorly Differentiated Neuroendocrine Carcinomas of the Digestive System: A Potential Target for Anti-PD-1/PD-L1 Therapy. Human Pathology, 70, 49-54. [Google Scholar] [CrossRef] [PubMed]
[52] Wang, H., Li, Z., Dong, B., Sun, W., Yang, X., Liu, R., et al. (2018) Prognostic Significance of PD-L1 Expression and CD8+ T Cell Infiltration in Pulmonary Neuroendocrine Tumors. Diagnostic Pathology, 13, Article No. 30. [Google Scholar] [CrossRef] [PubMed]
[53] Tian, Y., Zhen, L., Bai, J., Mei, Y., Li, Z., Lin, A., et al. (2017) Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors in Vitro and in Vivo. Pancreas, 46, 1076-1081. [Google Scholar] [CrossRef] [PubMed]
[54] 邱旭东. 中药联合生长抑素类似物治疗晚期胃肠胰神经内分泌肿瘤的相关研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2019.
[55] 张稚淳, 贾梦冉, 田劭丹, 等. 李佩文教授治疗胰腺癌经验探讨[J]. 天津中医药, 2019, 36(12): 1160-1162.
[56] 余芙欢, 李远良, 苏菲, 等. 芪贞抑瘤方预防胰腺神经内分泌肿瘤术后复发的回顾研究[J]. 中日友好医院学报, 2023, 37(1): 21-24.
[57] 陈天君, Asmit Thakar, 陈明伟. GP 化疗联合贞芪扶正胶囊治疗NSCLC的临床观察[J]. 时珍国医国药, 2012, 23(9): 2264-2265.
[58] 景明, 李沛清, 刘俊田, 等. 贞芪扶正分散片对肿瘤化疗的增效和减毒作用研究[J]. 时珍国医国药, 2010, 21(3): 604-605.